New drug SI-B001 tested for tough head and neck cancers
NCT ID NCT05044897
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a drug called SI-B001 in 11 adults with head and neck cancer that has returned or spread after prior treatments like chemotherapy and immunotherapy. The drug is given weekly through an IV. Researchers are checking if it can shrink tumors and how safe it is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SI-B001 (a drug given weekly by IV infusion)
- What this could lead to
- If it works, this could offer a new treatment option for people with head and neck cancer that has returned or spread after standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 11 participants, so results may not apply widely. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Oriental Hospital
Shanghai, Shanghai Municipality, 200000, China
-
The Affiliated Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China
-
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?